These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32199197)

  • 1. Evolving role of regorafenib for the treatment of advanced cancers.
    Grothey A; Blay JY; Pavlakis N; Yoshino T; Bruix J
    Cancer Treat Rev; 2020 Jun; 86():101993. PubMed ID: 32199197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib in gastrointestinal stromal tumors.
    Sirohi B; Philip DS; Shrikhande SV
    Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib: A Review in Hepatocellular Carcinoma.
    Heo YA; Syed YY
    Drugs; 2018 Jun; 78(9):951-958. PubMed ID: 29915898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib: A Review in Metastatic Colorectal Cancer.
    Dhillon S
    Drugs; 2018 Jul; 78(11):1133-1144. PubMed ID: 29943375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
    Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on the safety and efficacy of regorafenib in the treatment of solid cancers.
    Chan SL; Ma BB
    Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1607-14. PubMed ID: 25316322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
    Rimassa L; Pressiani T; Personeni N; Santoro A
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
    Shirley M; Keating GM
    Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib.
    Ettrich TJ; Seufferlein T
    Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
    Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
    Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
    Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
    Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
    Pelosof L; Lemery S; Casak S; Jiang X; Rodriguez L; Pierre V; Bi Y; Liu J; Zirkelbach JF; Patel A; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2018 Apr; 23(4):496-500. PubMed ID: 29386313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
    Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib for the treatment of hepatocellular carcinoma.
    Tovoli F; Granito A; De Lorenzo S; Bolondi L
    Drugs Today (Barc); 2018 Jan; 54(1):5-13. PubMed ID: 29569657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regorafenib.
    Ettrich TJ; Seufferlein T
    Recent Results Cancer Res; 2018; 211():45-56. PubMed ID: 30069758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
    Rutkowski P; Stępniak J
    Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
    Finn RS; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Gerolami R; Caparello C; Cabrera R; Chang C; Sun W; LeBerre MA; Baumhauer A; Meinhardt G; Bruix J
    J Hepatol; 2018 Aug; 69(2):353-358. PubMed ID: 29704513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes.
    Fukudo M; Asai K; Tani C; Miyamoto M; Ando K; Ueno N
    Invest New Drugs; 2021 Oct; 39(5):1422-1431. PubMed ID: 33830408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo.
    Poole CD; Connolly MP; Chang J; Currie CJ
    Gastric Cancer; 2015 Jul; 18(3):627-34. PubMed ID: 24957256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.